Actively Recruiting
Safety and Effectiveness of Total Pancreatectomy With Islet Autotransplantation for Treating Resectable Pancreas Region Adenocarcinoma at High Risk of Postoperative Fistula
Led by University Hospital, Lille · Updated on 2025-09-25
36
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a surgical approach for patients with locally resectable invasive adenocarcinomas in the cephalic region of the pancreas, duodenum, or ampulla of Vater who are at high risk of postoperative pancreatic fistula. The study compares the traditional pancreaticoduodenectomy followed by chemotherapy with total pancreatectomy combined with intraportal islet autotransplantation TPIAT. This approach aims to reduce complications that hinder completion of chemotherapy and maintain better metabolic control after surgery. The total pancreatectomy procedure involves removing all pancreatic tissue, eliminating the risk of postoperative pancreatic fistula but causing endocrine insufficiency and metabolic challenges like brittle diabetes. The study uses TPIAT to isolate islets from the removed pancreas and transplant them into the liver through intraportal infusion and forearm muscle injection. This transplant aims to preserve insulin production and improve quality of life. The study hypothesizes that TPIAT will increase completion rates of adjuvant chemotherapy while controlling glucose metabolism. Participants will be closely monitored with evaluations of chemotherapy completion rates at 12 months after surgery and various secondary outcomes up to 36 months, including postoperative complications, cancer recurrence, diabetes status, quality of life, adverse events, mortality, and islet graft function. Assessments include metabolic tests, imaging, questionnaires, and tracking of serious hypoglycemic events. The study provides long-term follow-up to assess safety and effectiveness of the combined surgical and autotransplantation treatment.
CONDITIONS
Brief Title
Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula
Research Team
F
François PATTOU, MD,PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here